Fancamp Awarded ECOLOGO Certification for Responsible Mineral Exploration from UL Solutions

(TSX-V:FNC), VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) — Fancamp Exploration Ltd. (“Fancamp” or the “Corporation“) (TSX Venture Exchange: FNC) is pleased to announce that it has achieved ECOLOGO(R) Certification for ULC TS-2723 Responsible Development for Mineral Exploration Industry (the “ECOLOGO(R) Certification“) from UL Solutions, a global leader in applied safety science. The UL […]

CAPREIT Announces Departure of Chief Investment Officer

(TSX:CAR-UN),(TSX:CAR.UN), This news release constitutes a “designated news release” for the purposes of CAPREIT's prospectus supplement dated May 15, 2025, to its short form base shelf prospectus dated May 15, 2025. Not for distribution to U.S. newswire services or for dissemination in the United States. TORONTO, Jan. 13, 2026 (GLOBE NEWSWIRE) — Canadian Apartment Properties

Jacobs to Hold Its Fiscal First Quarter 2026 Earnings Conference Call and Webcast

Jacobs (NYSE:J) plans to release its fiscal first quarter 2026 earnings results after market close on Tuesday, Feb. 3, 2026, and will host a conference call at 4:30 p.m. ET, during which management will make a presentation focusing on the company’s results and operating trends. Interested parties can listen to the conference call via a

Velocity Advisory Group Launches Activating Greatness, an Executive Podcast on Leadership, Culture, and Strategy

Velocity Advisory Group, a trusted firm specializing in leadership development and organizational strategy, today announced the launch of Activating Greatness, a new executive podcast designed to equip leaders with practical insight on leadership, cultural alignment, and strategy execution. Hosted by Alec McChesney, Director of Business Development at Velocity Advisory Group, the podcast features intriguing and

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO(R) (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO(R) (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States GlobeNewswire January 13, 2026 Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered

CAPREIT Announces Departure of Chief Investment Officer

CAPREIT Announces Departure of Chief Investment Officer GlobeNewswire January 13, 2026 This news release constitutes a “designated news release” for the purposes of CAPREIT's prospectus supplement dated May 15, 2025, to its short form base shelf prospectus dated May 15, 2025. Not for distribution to U.S. newswire services or for dissemination in the United States.

Fancamp Awarded ECOLOGO Certification for Responsible Mineral Exploration from UL Solutions

Fancamp Awarded ECOLOGO Certification for Responsible Mineral Exploration from UL Solutions GlobeNewswire January 13, 2026 VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) — Fancamp Exploration Ltd. (“Fancamp” or the “Corporation“) (TSX Venture Exchange: FNC) is pleased to announce that it has achieved ECOLOGO(R) Certification for ULC TS-2723 Responsible Development for Mineral Exploration Industry (the

Wolf Popper LLP Announces Investigation on Behalf of CVRx, Inc. Investors

(NASDAQ:CVRX), NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) — Wolf Popper LLP is investigating potential claims on behalf of purchasers of CVRx, Inc. (“CVRx”) common stock (NASDAQ: CVRX). CVRx is a medical device company. CVRx's principal product is Barostim, which acts like a pacemaker. On April 30, 2024, CVRx announced weak first quarter results, which

Wolf Popper LLP Announces Investigation on Behalf of CVRx, Inc. Investors

Wolf Popper LLP Announces Investigation on Behalf of CVRx, Inc. Investors GlobeNewswire January 13, 2026 NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) — Wolf Popper LLP is investigating potential claims on behalf of purchasers of CVRx, Inc. (“CVRx”) common stock (NASDAQ: CVRX). CVRx is a medical device company. CVRx's principal product is Barostim, which acts

/C O R R E C T I O N — Armata Pharmaceuticals, Inc./

In the news release, Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus, issued Jan. 13, 2026 by Armata Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that the original version contained incorrect information introduced by PR Newswire during

Scroll to Top